GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (NAS:TBPH) » Definitions » PS Ratio

Theravance Biopharma (Theravance Biopharma) PS Ratio : 8.57 (As of Apr. 29, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Theravance Biopharma's share price is $9.13. Theravance Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.07. Hence, Theravance Biopharma's PS Ratio for today is 8.57.

Good Sign:

Theravance Biopharma Inc stock PS Ratio (=8.79) is close to 2-year low of 8.06

The historical rank and industry rank for Theravance Biopharma's PS Ratio or its related term are showing as below:

TBPH' s PS Ratio Range Over the Past 10 Years
Min: 7.02   Med: 17.1   Max: 982.57
Current: 8.57

During the past 12 years, Theravance Biopharma's highest PS Ratio was 982.57. The lowest was 7.02. And the median was 17.10.

TBPH's PS Ratio is ranked better than
51.16% of 993 companies
in the Biotechnology industry
Industry Median: 8.99 vs TBPH: 8.57

Theravance Biopharma's Revenue per Sharefor the three months ended in Dec. 2023 was $0.36. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.07.

Warning Sign:

Theravance Biopharma Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Theravance Biopharma was 48.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -3.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was -7.30% per year. During the past 10 years, the average Revenue per Share Growth Rate was 28.80% per year.

During the past 12 years, Theravance Biopharma's highest 3-Year average Revenue per Share Growth Rate was 437.70% per year. The lowest was -32.60% per year. And the median was -3.40% per year.

Back to Basics: PS Ratio


Theravance Biopharma PS Ratio Historical Data

The historical data trend for Theravance Biopharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma PS Ratio Chart

Theravance Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.61 15.41 13.88 16.07 10.83

Theravance Biopharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.07 15.63 13.07 9.31 10.83

Competitive Comparison of Theravance Biopharma's PS Ratio

For the Biotechnology subindustry, Theravance Biopharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's PS Ratio falls into.



Theravance Biopharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Theravance Biopharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=9.13/1.065
=8.57

Theravance Biopharma's Share Price of today is $9.13.
Theravance Biopharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.07.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Theravance Biopharma  (NAS:TBPH) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Theravance Biopharma PS Ratio Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theravance Biopharma (Theravance Biopharma) Business Description

Traded in Other Exchanges
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Executives
Rhonda Farnum officer: SVP, Comm & Medical Affairs 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Richard A Graham officer: SVP, Development 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Kelly James Connor director 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Brett A. Grimaud officer: SVP, Gen Counsel and Secretary 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Aziz Sawaf officer: SVP & Chief Financial Officer 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Rick E Winningham director, officer: Chief Executive Officer 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Andrew A. Hindman officer: SVP, Chief Financial Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Eli Samaha 10 percent owner ONE WORLD TRADE CENTER, FLOOR 65, NEW YORK NY 10007
Wam Gp Llc 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Andrew M Weiss 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Weiss Asset Management Lp 10 percent owner 222 BERKELEY STREET, 16TH FLOOR, BOSTON MA 02116
Philip D Worboys officer: SVP, Translational Science 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Brett K Haumann officer: VP-Clinical Develop. 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080
Deepika Pakianathan director 160 BOVET ROAD, SUITE 408, C/O DELPHI VENTURES, SAN MATEO CA 94402

Theravance Biopharma (Theravance Biopharma) Headlines